08:48 AM EDT, 09/05/2024 (MT Newswires) -- Voyager Therapeutics ( VYGR ) said Thursday that Novartis ( NVS ) has agreed to license a novel capsid to use in a gene therapy program against an undisclosed rare neurologic disease target.

The biotech firm said the capsid license is being granted under an agreement between the two companies that was originally announced in March 2022.

Shares of Voyager rose more than 5% in recent premarket activity Thursday, while Novartis ( NVS ) lost more than 1% recently.

Price: 6.54, Change: +0.34, Percent Change: +5.48